Analysis of outcomes in metastatic pancreatic cancer: Real-world experience in academic cancer centers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.458
Abstract: 458Background: FOLFIRINOX is an active regimen for metastatic pancreatic cancer demonstrating a median overall survival of 11.1 months at the expense of significant treatment-related toxicity. Dose modifications are routinely used in clinical practice however there… read more here.
Keywords: metastatic pancreatic; analysis outcomes; pancreatic cancer; cancer real ... See more keywords